Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Prostate cancer drug degarelix tested for Long-Term safety

NCT ID NCT00117286

Disease control Sponsor: Ferring Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the long-term safety of the drug degarelix in 57 men with prostate cancer. Participants received a monthly injection of degarelix for up to 5 years. The goal was to monitor side effects, such as changes in blood pressure, pulse, weight, and liver function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Degarelix (a hormone-blocking drug given as a monthly injection)
What this could lead to
If successful, this could confirm that long-term use of degarelix is safe for controlling prostate cancer.
What could go wrong
This is an extension study focused on safety, not on how well the drug works. The small number of participants (57) limits how much we can learn about rare side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

57 people

The number who actually took part.

Start date

Mar 2005

Finished

Nov 2009

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has given written consent prior to any study-related activity being performed. A study-related activity is defined as any procedure that would not have been performed during the normal management of the patient. * Has completed study FE200486 CS14 through visit 22. Exclusion Criterion: * Has been withdrawn from the FE200486 CS14 study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • Advanced Urology Medical Center

    Anaheim, California, 92801, United States

  • Brantford Urology Research

    Brantford, Ontario, N3R4N3, Canada

  • Burlington Professional Care

    Burlington, Ontario, L7N3V2, Canada

  • Can-Med Clinical Research, Inc.

    Victoria, British Columbia, V8T5G1, Canada

  • Investigational site

    Seattle, Washington, 98166, United States

  • Lawrenceville Urology

    Lawrenceville, New Jersey, 08648, United States

  • Northeast Indiana Research, LLC

    Fort Wayne, Indiana, 46825, United States

  • Regional Urology

    Shreveport, Louisiana, 71106, United States

  • SW Florida Urological Associates

    Fort Myers, Florida, 33907, United States

  • South Florida Medical Research

    Aventura, Florida, 33180, United States

  • State College Urologic Association

    State College, Pennsylvania, 16801, United States

  • The Female/Male Health Centres

    Oakville, Ontario, L6H3P1, Canada

  • The Male and Female Health and Research Centers

    Barrie, Ontario, L4M7G1, Canada

  • The Urology Center

    Greensboro, North Carolina, 27401, United States

  • University Urological Research Institute

    Providence, Rhode Island, 02904, United States

  • University of Vermont, Dept of Surgery

    South Burlington, Vermont, 05403, United States

  • Urology Associate PC'

    Denver, Colorado, 80210, United States

  • Urology Centers of Alabama

    Homewood, Alabama, 35209, United States

  • Urology San Antonio Research

    San Antonio, Texas, 78229, United States

  • Virginia Urology Center

    Richmond, Virginia, 23235, United States

  • West Coast Clinical Research

    Tarzana, California, 91356, United States

  • Western Clinical Research

    Torrance, California, 90505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.